Fighting for Crumbs

Fighting for Crumbs

With Abbott reporting first quarter results this morning it’s about time to acknowledge some very pesky facts.

1. Libre sales not surprisingly were strong.

2. As Abbott CEO Robert Ford noted reimbursement for CGM continues to improve.

3. Surprisingly Mr. Ford seemed realistic about gaining share now that Libre is integrated with the Control IQ and Omnipod 5.

4. Equally surprising was his claim that Libre is doing well in the non-intensive insulin market.

5. Libre has achieved has the scale necessary that even with internal bickering sales continue . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.